Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1E | P28566 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942971 | 0.93 | QDPR (0.46) | QDPRCSF1RKITCYP2C19PRKAB2 | |
| Trifluoroacetic Acid SCHEMBL3085129 | 0.90 | QDPR (0.43) | QDPRTPSAB1CSF1RKITCYP2C19 | |
| SCHEMBL2942972 | 0.82 | QDPR (0.49) | QDPRCSF1RKITCYP2C19PRKAB2 | |
| SCHEMBL2908024 | 0.81 | CSF1R (0.48) | QDPRCSF1RKITCYP2C19PRKAA2 | |
| SCHEMBL2910201 | 0.78 | CSF1R (0.54) | QDPRCSF1RKITCYP2C19PRKAA2 | |
| Trifluoroacetic Acid SCHEMBL3093525 | 0.76 | CSF1R (0.53) | QDPRCSF1RKITADRB3DRD1 | |
| Trifluoroacetic Acid SCHEMBL3081618 | 0.76 | CSF1R (0.53) | CSF1RKITCYP2C19PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL2907598 | 0.75 | CSF1R (0.56) | CSF1RKITCYP2C19ADRB3DRD1 | |
| Trifluoroacetic Acid SCHEMBL15399760 | 0.75 | CSF1R (0.53) | CSF1RKITCYP2C19PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL3173774 | 0.74 | KIT (0.53) | CSF1RKITCYP2C19PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| EP-2397138-B1 | Aromatic amide derivatives as C-KIT kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7795279-B2 | Method of inhibiting FLT3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1898912-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007124369-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | QDPR 4792/4885TPSAB1 721/4885CSF1R 34/4885 |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | SOST, CALCB, CALCA | QDPR 2284/4885TPSAB1 190/4885CSF1R 304/4885 |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | QDPR 1086/4885TPSAB1 336/4885CSF1R 2973/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | QDPR 2782/4885TPSAB1 797/4885CSF1R 3/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | QDPR 4792/4885TPSAB1 721/4885CSF1R 34/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | QDPR 1086/4885TPSAB1 336/4885CSF1R 2973/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | QDPR 2795/4885TPSAB1 1499/4885CSF1R 149/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | QDPR 1086/4885TPSAB1 336/4885CSF1R 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.